2.2 Indications The currently approved indications for these agents include: Type 2 diabetes mellitus Overweight and obesity Beyond diabetes and obesity, further indications under investigation for GLP1 RAs include: Osteoarthritis Obstructive sleep apnea Metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatohepatitis 2.3 Benefits and Harms of Continuation/Discontinuation in the Perioperative Period: 2.3.1 Benefits: According to the guidelines, the acute use of these drugs may offer benefits based on published data: Improved perioperative glycemic control Lower postoperative insulin requirements Reduced risk of hypoglycemia These benefits may lead to reduced complications associated with hyperglycemia (such as a shorter hospital stay, fewer surgical site infections, less acute kidney injury, fewer acute coronary syndromes, reduced critical care admissions, and shorter durations on a ventilator) Improved cardiovascular outcomes 2.3.2 Harms There is an increased risk of pulmonary aspiration
Cavazos A, Ma H, Han L, Cai T, Zhang Q, Harutyunyan K, Baran N, Zhang W, Daver N, Andreeff M , Ashoorzadeth A, Anderson R, Patterson A, Smaill JB, Konopleva
Use according to batch specification after opening
Our program has helped many individuals achieve their goals, and experience improvements in their overall health and well-being
